|
Saturday,
May 3, 2003
9:30am
– 11:30am
PAS
Educational Workshops
See
the PAS Daily Program
12:00pm
– 3:00pm
Mini
Courses & Educational Workshops
See
the PAS Daily Program
3:15pm
– 5:15pm
Infectious
Diseases and/or Neonatal Infectious Diseases Platform
Session
PAS/PIDS
Original Science Abstracts
5:15pm
– 7:15pm
Neonatal
Infectious Diseases and/or Infectious Diseases Posters I
Poster
Session I, PAS Opening Reception & Exhibits
PAS/PIDS
Original Science Abstracts
Sunday,
May 4, 2003
7:00am
– 8:00am
Meet the Professor Breakfasts
TICKETED
EVENTS
VENT
-
Advance Sign Up Required.
-
Attendance
is limited to maintain the intimate interactive format
and only 25 tickets will be assigned to each of these
special sessions. These sessions will fill quickly.
-
To
register, use the registration form on page 69
4052
Infectious Diseases
PAS
Meet the Professor Breakfast
The
Challenges of Clinical Research in Infectious Diseases; The
Good, The Bad and the Ugly
Kathryn M. Edwards, Vanderbilt University School of
Medicine, Nashville, TN
In
this session the speaker will use a randomized placebo
controlled vaccine efficacy trial to demonstrate the needed
elements of a well conducted clinical trial. In addition to
discussing the fundamental elements of a clinical trial, the
speaker will also discuss the practical implications of
clinical research in one’s career, how one integrates
clinical studies into the broader context of academic life
and how one prepares for such a career. Ample time for
discussion will be available to the participants about all
phases of the presentation.
8:00am
– 10:00am
4102 Smallpox
and Bioterrorism Preparedness Planning
PAS/PIDS
Topic Symposium
Chair: John
F. Modlin, Children’s Hospital at Dartmouth/Dartmouth
Medical School, Lebanon, NH
This program will give
a “pediatric perspective” to smallpox bioterrorism
preparedness planning efforts now under way within federal,
state and local public health agencies. It will include a
review of smallpox epidemiology, clinical disease, smallpox
(vaccinia) vaccine and lessons learned from the WHO Smallpox
Eradication Program. The nature of the current threat and
responses to that threat will be discussed.
Smallpox
Epidemiology and Clinical Disease
Walter
A. Orenstein, National Immunization Program, Centers for
Disease Control and Prevention, Atlanta, GA
Control and
Eradication of Smallpox
J.
Michael Lane, Emory University School of Medicine, Atlanta,
GA
Smallpox (Vaccinia)
Vaccine: Efficacy and Complications
John
M. Neff, Children’s Hospital and Regional Medical Center,
Seattle, WA
Smallpox
Bioterrorism Preparedness Planning
John
F. Modlin, Children’s Hospital at Dartmouth/Dartmouth
Medical School, Lebanon, NH
11:45am
– 1:45pm
Neonatal
Infectious Diseases and/or Infectious Diseases Posters II
PAS Poster Session II & Exhibits
PAS/PIDS
Original Science Abstracts
2:30pm
– 4:00pm
4731
Neonatal Herpes Simplex Virus (HSV) Infections:
Current Controversies
PAS/PIDS
State of the Art
Chair: Richard
J. Whitley, University of Alabama at Birmingham,
Children’s Hospital, Birmingham, AL
This State of the Art
Plenary will be of interest to practitioners, generalists,
neonatologists and infectious diseases specialists and will
explore current controversies in the diagnosis and
management of neonatal HSV infection.
Speakers will present maternal factors that may allow
interruption of maternal–fetal transmission of the virus,
the latest strategies for diagnosis and treatment of
newborns, and the potential prevention of neonatal HSV by
use of pre-emptive antiviral therapy and vaccines.
Maternal–Fetal
Transmission: Risks and Opportunities
Ann
M. Arvin, Stanford University School of Medicine, Stanford,
CA
Diagnosis and
Treatment of Neonatal HSV
Richard
J. Whitley, University of Alabama at Birmingham,
Children’s Hospital, Birmingham, AL
Prevention of
Neonatal HSV Infection:
Are Vaccines the Answer?
Lawrence
R. Stanberry, University of Texas Medical Branch, Galveston,
TX
Discussion
Questions from
the Audience and Answers from the Experts
Audience Moderators:
Gail
J. Demmler, Baylor College of Medicine, Houston, TX and
Larry Givner, Wake Forest University, Winston-Salem, NC
4:15pm
– 6:15pm
4850
Current Research Issues in STDs and Adolescents:
Chlamydia, Genital Herpes and Human Papillomavirus Infection
PAS/PIDS
Topic Symposium
Chair: Donald
E. Greydanus, Michigan State University Kalamazoo Center for
Medical Studies, Kalamazoo, MI
This session reviews
current research principles in selected sexually transmitted
diseases. First,
clinical epidemiology and prevention issues for Chlamydia
trachomatis are considered, emphasizing rescreening
(delayed retesting of infected persons), novel strategies
for assuring partner treatment and the role of male
screening in disease control.
Then, new directions in public health and prevention
aspects of genital herpes are outlined.
An update of the HSV vaccine is presented.
Finally, human papillomavirus (HPV) is considered,
including new recommendations in human papillomavirus
testing, triage of abnormal Pap smears and the current
status of HPV vaccines.
Questions are encouraged from the audience.
Chlamydia
H.
Hunter Handsfield, University of Washington and Public
Health - Seattle & King County, Seattle, WA
Genital Herpes
Anna
Wald, University of Washington Virology Research Clinic,
Seattle, WA
Human
Papillomavirus Infection
Anna-Barbara
Moscicki, Glaser Pediatric Research Network, University of
California, San Francisco, CA
Epidemiology of
STDs in Children and Adolescents: Perspectives from the
World Health Organization
Nathalie
Broutet, World Health Organization, Geneva, Switzerland
Monday,
May 5, 2003
8:00am
– 10:00am
Neonatal
Infectious Diseases and/or Infectious Diseases Abstract
Session
PAS/PIDS
Original Science Abstracts
1:00pm
– 2:45pm
March
of Dimes Prize in Developmental Biology Lectures
3:00pm
– 5:00pm
5654
Vaccines—2003
PAS/PIDS
Topic Symposium
Chair:
Stanley A. Plotkin, Aventis Pasteur and the
University of Pennsylvania, Doylestown, PA
This symposium covers
four issues in vaccination.
The American Academy of Pediatrics and CDC currently
are moving toward a recommendation for universal annual
vaccination of infants with killed or live influenza
vaccine. Why is this? Now
that Rotashield is off the market, a new rotavirus vaccine
is needed and may be on the way.
Despite good protection of children by vaccination,
pertussis infections are rising in adolescents and adults.
Can they be controlled?
Recent disruptions in vaccine supply have caused
pediatricians significant problems.
What are the causes and solutions?
Universal
Influenza Vaccination in Children
W.
Paul Glezen, Baylor College of Medicine, Houston, TX
New Rotavirus
Vaccines: After Rotashield
Paul
A. Offit, Children’s Hospital of Philadelphia,
Philadelphia, PA
Adolescent and
Adult Pertussis Vaccination
Kathryn
M. Edwards, Vanderbilt University School of Medicine,
Nashville, TN
Vaccine
Shortages: Causes and Effects
Walter
A. Orenstein, National Immunization Program, Centers for
Disease Control and Prevention, Atlanta, GA
5:00pm
– 6:00pm
PIDS
Business Meeting
6:15pm
5955A
PIDS Annual Dinner & Awards Banquet
Grand Hyatt
Seattle
Tuesday,
May 6, 2003
8:00am
– 10:00am
Related
Infectious Diseases Abstract Session
PAS/PIDS
Original Science Abstracts
10:15am
– 11:45am
6302
New Directions in Newborn and Pediatric Sepsis and
Multiple Organ Failure
PAS/PIDS
State of the Art
Chair: Joseph
A. Carcillo, University of Pittsburgh School of Medicine,
Pittsburgh, PA
Severe sepsis is an
important and relatively neglected public health problem in
the United States. National
estimates show that more children die with severe sepsis
than die with cancer.
Despite improving national outcomes (10% mortality in
1995 and 9% mortality in 1999), the burden of severe sepsis
continues to increase in the US with an estimated associated
annual cost of 4 billion dollars.
There is cause for
continued optimism in the field.
In 1968, 96% of children with severe gram negative
sepsis died. Early
recognition and aggressive fluid resuscitation has been
credited with improved outcomes from septic shock (St.
Mary’s Hospital reported a 5% mortality rate in
meningococcal septic shock/purpura fulminans, and
investigators in Vietnam reported a 0% mortality rate in
Dengue shock in 2001).
Unlike adults, who die of vascular failure, newborns
and children who die of fluid refractory septic shock do so
from cardiac failure. The American College of Critical Care
Medicine published age-specific evidence-based guidelines
for management of newborn and pediatric shock in 2002.
Understanding of the
pathophysiology and potential treatment of sepsis-induced
multiple organ failure is also rapidly advancing.
Thrombocytopenia associated multiple organ failure
has been further characterized as a thrombotic
microangiopathy. Twenty
percent of these patients have disseminated intravascular
coagulation pathophysiology (unopposed tissue factor
activity and consumptive coagulopathy), but 80% have
thrombotic thrombocytopenic purpura pathophysiology
(increased ultra large vWF multimers and decreased vWF
cleaving protease activity).
This has great therapeutic implications because
recombinant technology is rapidly producing human
coagulation-related proteins (e.g., activated protein C, vWF
cleaving protease, tissue plasminogen activator), and
prolonged plasma exchange therapy is a proven therapy that
reverses TTP pathophysiology.
Up to 80% of children who die with sepsis do so with
multiple organ failure and uneradicated infection.
Primary and acquired immunodeficiency states
contribute to most of these poor outcomes.
Prolonged neutropenia, lymphopenia, and
hypogammaglobulinemia are readily measured in the clinical
laboratory but research measurements (monocyte HLA-DR
expression, and ex vivo whole blood TNF a response to LPS
stimulation) are required to diagnose prolonged monocyte
deactivation and immuneparalysis. Diagnosis of these immunodeficiency syndromes can have great
therapeutic implications as tapering of immune suppression
and use of recombinant growth factors (e.g., G-CSF, GM-CSF,
interferon) and prophylaxis strategies can improve outcome
in these children.
Newborn and
Pediatric Sepsis and Multiple Organ Failure
Joseph
A. Carcillo, University of Pittsburgh School of Medicine,
Pittsburgh, PA
Hypodynamic
Septic Shock: The Heart as an Innate Immune Response Organ
Brett
P. Giroir, University of Texas Southwestern Medical Center,
Dallas, TX
Thrombocytopenia-Associated
Multiple Organ Failure: The Role of ADAMTS13
Trung
Nguyen, University of Pittsburgh School of Medicine,
Pittsburgh, PA
Prolonged
Monocyte Deactivation and Unresolving Multiple Organ
Failure: A TH2-Like
Paradigm
Mark
Hall, Ohio State University School of Medicine, Columbus, OH
|
